Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2002-06-30

Study Completion Date

2004-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00109876

Lung Cancer

COMPLETED NA

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

NCT00024076

Lung Cancer Malignant Mesothelioma Metastatic Cancer +1 more

COMPLETED PHASE2

Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00499447

Lung Cancer

COMPLETED NA

Radiofrequency Ablation of Lung Tumors

NCT00180856

Lung Cancer Metastasis

COMPLETED PHASE2

Protocol for Radiofrequency Ablation of Pulmonary Neoplasms

NCT00232128

Pulmonary Neoplasms

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in patients with resectable non-small cell lung cancer.
* Determine the treatment-related toxicity in patients treated with this therapy.
* Determine the dimensions of the RFA lesion produced by the ablation procedure in these patients.

OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes for each tumor immediately followed by tumor resection.

PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

conventional surgery

Intervention Type PROCEDURE

radiofrequency ablation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of malignant non-small cell lung cancer (NSCLC)

* Intraoperative needle biopsy confirmation allowed
* Resectable disease (stage I or II)
* All tissue to be treated by radiofrequency tumor ablation must be completely contained within boundaries of planned lung resection
* Medically fit to undergo lung resection

PATIENT CHARACTERISTICS:

Age:

* Over 18

Performance status:

* Not specified

Life expectancy:

* Not specified

Hematopoietic:

* Not specified

Hepatic:

* Not specified

Renal:

* Not specified

Other:

* Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* No prior or concurrent biologic therapy

Chemotherapy:

* No prior or concurrent chemotherapy

Endocrine therapy:

* No prior or concurrent endocrine therapy

Radiotherapy:

* No prior or concurrent radiotherapy

Surgery:

* See Disease Characteristics

Other:

* No other prior therapy for NSCLC

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No